Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Balmer

Showing results (1-10 of 77) with videos related to

Pageof 8
Sort By:
Expert Review of Vaccines|February 6, 2004
Serologic correlates of protection for evaluating the response to meningococcal vaccinesPaul Balmer, Ray Borrow
Infection and Immunity|March 16, 2002
NK T cells are a source of early interleukin-4 following infection with third-stage larvae of the filarial nematode Brugia pahangiPaul Balmer, Eileen Devaney
Vaccine|June 5, 2007
Issues surrounding standardization of meningococcal group W135 serologyPaul Balmer, Ray Borrow
Current Opinion in Infectious Diseases|May 17, 2002
Meningococcal disease: how to prevent and how to managePaul Balmer, Elizabeth Miller
Therapeutic Advances in Vaccines and Immunotherapy|September 6, 2018
Optimal use of meningococcal serogroup B vaccines: moving beyond outbreak controlPaul Balmer, Laura J York
Vaccine|March 10, 2005
Meningococcal surrogates of protection--serum bactericidal antibody activityRay Borrow, Paul Balmer, Elizabeth Miller
Human Vaccines & Immunotherapeutics|March 19, 2019
A review of complement sources used in serum bactericidal assays for evaluating immune responses to meningococcal ACWY conjugate vaccinesJamie Findlow, Paul Balmer, Ray Borrow
Pharmacotherapy|June 23, 2016
History of Meningococcal Outbreaks in the United States: Implications for Vaccination and Disease PreventionBruce Atkinson, Ashesh Gandhi, Paul Balmer
Postgraduate Medicine|July 29, 2016
Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba®)Ashesh Gandhi, Paul Balmer, Laura J York
Vaccine|July 17, 2007
The 23-valent pneumococcal polysaccharide vaccine does not provide additional serotype antibody protection in children who have been primed with two doses of heptavalent pneumococcal conjugate vaccinePaul Balmer, Ray Borrow, Peter D Arkwright
Pageof 8

Showing results (1-10 of 77) with videos related to

Sort By:
Pageof 8
Expert Review of Vaccines|February 6, 2004
Serologic correlates of protection for evaluating the response to meningococcal vaccinesPaul Balmer, Ray Borrow
Infection and Immunity|March 16, 2002
NK T cells are a source of early interleukin-4 following infection with third-stage larvae of the filarial nematode Brugia pahangiPaul Balmer, Eileen Devaney
Vaccine|June 5, 2007
Issues surrounding standardization of meningococcal group W135 serologyPaul Balmer, Ray Borrow
Current Opinion in Infectious Diseases|May 17, 2002
Meningococcal disease: how to prevent and how to managePaul Balmer, Elizabeth Miller
Therapeutic Advances in Vaccines and Immunotherapy|September 6, 2018
Optimal use of meningococcal serogroup B vaccines: moving beyond outbreak controlPaul Balmer, Laura J York
Vaccine|March 10, 2005
Meningococcal surrogates of protection--serum bactericidal antibody activityRay Borrow, Paul Balmer, Elizabeth Miller
Human Vaccines & Immunotherapeutics|March 19, 2019
A review of complement sources used in serum bactericidal assays for evaluating immune responses to meningococcal ACWY conjugate vaccinesJamie Findlow, Paul Balmer, Ray Borrow
Pharmacotherapy|June 23, 2016
History of Meningococcal Outbreaks in the United States: Implications for Vaccination and Disease PreventionBruce Atkinson, Ashesh Gandhi, Paul Balmer
Postgraduate Medicine|July 29, 2016
Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba®)Ashesh Gandhi, Paul Balmer, Laura J York
Vaccine|July 17, 2007
The 23-valent pneumococcal polysaccharide vaccine does not provide additional serotype antibody protection in children who have been primed with two doses of heptavalent pneumococcal conjugate vaccinePaul Balmer, Ray Borrow, Peter D Arkwright
Pageof 8